CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
Subscribe To Our Newsletter & Stay Updated
